ACTA ENDOCRINOLOGICA-BUCHAREST, cilt.14, sa.1, ss.55-65, 2018 (SCI-Expanded)
Context. There is no consensus regarding routine usage and benefits of molecular markers for prediction of prognosis and assessment of risk groups in differentiated thyroid cancer (DTC).